256 related articles for article (PubMed ID: 34301311)
1. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
Iwamoto N; Sato S; Kurushima S; Michitsuji T; Nishihata S; Okamoto M; Tsuji Y; Endo Y; Shimizu T; Sumiyoshi R; Suzuki T; Okada A; Koga T; Kawashiri SY; Fujikawa K; Igawa T; Aramaki T; Ichinose K; Tamai M; Nakamura H; Mizokami A; Origuchi T; Ueki Y; Eguchi K; Kawakami A
Arthritis Res Ther; 2021 Jul; 23(1):197. PubMed ID: 34301311
[TBL] [Abstract][Full Text] [Related]
2. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice.
González-Freire L; Giménez-Candela RM; Castro-Luaces S; Veiga-Villaverde AB; Crespo-Diz C
Farm Hosp; 2021 Jun; 45(4):165-169. PubMed ID: 34218760
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindström U; Turesson C; Frisell T
Rheumatology (Oxford); 2022 Oct; 61(10):3952-3962. PubMed ID: 35134119
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.
Iwamoto N; Tsuji S; Takatani A; Shimizu T; Fukui S; Umeda M; Nishino A; Horai Y; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Origuchi T; Eguchi K; Ueki Y; Kawakami A
PLoS One; 2017; 12(5):e0177057. PubMed ID: 28472115
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
12. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
[TBL] [Abstract][Full Text] [Related]
13. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis.
Martinez-Molina C; Diaz-Torne C; Park HS; Feliu A; Vidal S; Corominas H
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541086
[No Abstract] [Full Text] [Related]
15. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
16. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.
Qian J; Xue X; Shannon J
J Manag Care Spec Pharm; 2022 Sep; 28(9):1046-1052. PubMed ID: 36001100
[No Abstract] [Full Text] [Related]
20. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
